Invasive Fungal Infections Market Report 2026

The invasive fungal infections market size has grown steadily in recent years. It will grow from $7.91 billion in 2025 to $8.24 billion in 2026 at a compound annual growth rate (CAGR) of 4.1%. The growth in the historic period can be attributed to increasing prevalence of hiv and cancer patients, widespread use of broad-spectrum antibiotics, established use of amphotericin b in hospitals, growth in organ transplant procedures, rising incidence of hospital-acquired fungal infections.

The invasive fungal infections market size is expected to see strong growth in the next few years. It will grow to $10.1 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to development of novel antifungal drug classes, increasing awareness of antifungal resistance, expansion of critical care infrastructure, improved diagnostic capabilities for fungal infections, growing investment in infectious disease research. Major trends in the forecast period include rising incidence of invasive fungal infections in immunocompromised patients, increasing adoption of echinocandins as first-line therapy, growing use of combination antifungal treatment strategies, expansion of hospital-based antifungal stewardship programs, rising demand for broad-spectrum and targeted antifungal agents.

The increasing number of people affected by human immunodeficiency virus (HIV) is expected to drive the growth of the invasive fungal infection market in the coming years. HIV (Human Immunodeficiency Virus) is a virus that weakens the immune system, reducing its ability to fight off diseases and infections. The growing population with weakened immune systems, including those with HIV (Human Immunodeficiency Virus) or AIDS (acquired immunodeficiency syndrome), is more susceptible to invasive fungal infections, creating opportunities for manufacturers to develop and provide specialized and more effective antifungal medications. For example, in July 2025, the Joint United Nations Programme on HIV/AIDS (UNAIDS), a Switzerland-based international organization, reported that 40.8 million [37 million-45.6 million] people were living with HIV in 2024. In the same year, approximately 1.3 million [1 million-1.7 million] individuals contracted new HIV infections, while 630,000 [490,000-820,000] people died due to AIDS-related illnesses. Consequently, the growing population affected by human immunodeficiency virus (HIV) is expected to fuel the growth of the invasive fungal infection market.

Major companies in the invasive fungal infection market are concentrating on innovative products such as Zisavel capsules to enhance treatment effectiveness, improve patient outcomes, and expand accessibility for individuals affected by serious fungal infections. Zisavel capsules are a generic antifungal medication based on isavuconazole, developed to treat invasive aspergillosis and mucormycosis. These 100 mg capsules aim to offer an affordable alternative for patients, improving access to effective therapy. For example, in October 2023, BDR Pharmaceuticals, an India-based generic and specialty pharmaceutical company, introduced a generic antifungal drug, Zisavel Capsules, for the treatment of invasive aspergillosis and mucormycosis. Zisavel is indicated for treating invasive aspergillosis and mucormycosis, both of which are severe fungal infections with potentially life-threatening consequences. The launch of Zisavel seeks to make treatment more accessible to patients by substantially reducing costs compared to existing options such as voriconazole and posaconazole.

In August 2023, Sandoz, a Germany-based pharmaceutical company specializing in generic medicines and biosimilars, acquired Astellas Pharma Inc. for an undisclosed sum. Through this acquisition, Sandoz aims to strengthen its portfolio of generic and biosimilar products, broaden its market presence, and utilize synergies to foster growth and innovation in the pharmaceutical industry. Astellas Pharma Inc. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing, and marketing of innovative medications.

Major companies operating in the invasive fungal infections market are Pfizer Inc., Merck And Co. Inc., Bayer AG, Abbott Laboratories, GSK plc, Gilead Sciences Inc., Mylan N.V., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., BioMarin Pharmaceutical Inc., Xellia Pharmaceuticals, Basilea Pharmaceutica, Cidara Therapeutic Inc., Pulmocide Ltd., NovaBiotics Ltd, F2G Ltd., Giner Inc., Ciron Drugs And Pharmaceuticals Pvt. Ltd., Hexima Limited, Scynexis Inc., Enzon Pharmaceuticals Inc., Matinas BioPharma Holdings Inc., Biosergen AB.

North America was the largest region in the invasive fungal infections market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the invasive fungal infections market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the invasive fungal infections market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the invasive fungal infections market by increasing costs for imported antifungal drugs, active pharmaceutical ingredients, and specialized formulations. Hospitals and specialty clinics are most impacted, particularly in regions reliant on global pharmaceutical supply chains such as north america and asia pacific. These tariffs have raised treatment and procurement costs. However, they have also encouraged domestic drug manufacturing, alternative sourcing strategies, and innovation in cost-effective antifungal therapies.

The invasive fungal infections market research report is one of a series of new reports that provides invasive fungal infections market statistics, including invasive fungal infections industry global market size, regional shares, competitors with a invasive fungal infections market share, detailed invasive fungal infections market segments, market trends and opportunities, and any further data you may need to thrive in the invasive fungal infections industry. This invasive fungal infections market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Invasive fungal infections are severe diseases caused by pathogenic fungi that invade and spread within the body beyond the initial site of infection. These infections involve the penetration of fungal organisms into deeper tissues, including the bloodstream, organs, or other body structures. Treatment for invasive fungal infections generally involves the use of antifungal medications and, in certain cases, surgical procedures to remove infected tissue.

The primary types of invasive fungal infections include candidemia and invasive candidiasis, intraabdominal candidiasis, cryptococcal meningitis, esophageal candidiasis, acute pulmonary histoplasmosis, and others. Candidemia and invasive candidiasis are caused by Candida fungi and can affect the blood, heart, brain, eyes, bones, or other parts of the body. These infections are treated with medications such as polyenes, triazoles, echinocandins, flucytosine, and others, with end users including hospitals, homecare providers, specialty clinics, and more.

The invasive fungal infections market consists of revenues earned by entities by providing services such as diagnostic testing, clinical research and development, educational programs, and awareness campaign services. The market value includes the value of related goods sold by the service provider or included within the service offering. The invasive fungal infections market also includes sales of azoles, allylamines, and morpholines, which are used in treating invasive fungal infections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.